Clinical trials: Cirrhosis Portal
Hepatic Encephalopathy Stage 2, Hepatic Encephalopathy Stage 3
Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy
The goal of this clinical trial is to compare the efficacy of L-ornithine L-aspartate and Polyethylene Glycol in Cirrhotic Patients with Overt Hepatic Encephalopathy.
- Conditions
- Hepatic Encephalopathy Stage 2, Hepatic Encephalopathy Stage 3, Hepatic Encephalopathy Stage 4
- Trial name
- NCT05920213
- Testing
- Polyethylene Glycols, Lactulose oral solution, L-ornithine L-aspartate
- Where
- 6 sites in Pakistan
- Volunteers
- 360 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Portal Hypertension Related to Cirrhosis
Carvedilol vs Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding
Subjects will be those individuals greater than 18 years of age with a diagnosis of cirrhosis undergoing screening for esophageal varices.
- Trial name
- NCT02066649
- Testing
- Carvedilol, Variceal band ligation
- Where
- United States
- Sponsor
- Rutgers, The State University of New Jersey
Liver Fibrosis, Beta Thalassemia Major
Elastography vs Iron Regulators in the Diagnosis of Hepatic Fibrosis- Iron Overload in Children With Beta- Thalassemia
The goal of this cross-sectional observational study is to evaluate the accuracy of serum ferritin and serum hepcidin versus non-invasive scores in the diagnosis of liver fibrosis and iron overload in beta- thalassemia children.
- Trial name
- NCT07153926
- Testing
- Serum ferritin, Serum hepcidin
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Tanta University
Acute Kidney Injury, Cirrhosis
NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients
The goal of this pilot, randomized, single-blind clinical trial is to estimate the effect size of a high and low mean arterial pressure (MAP)-target algorithm among cirrhosis patients hospitalized with acute kidney injury.
- Conditions
- Acute Kidney Injury, Cirrhosis, Portal Hypertension, Hepatorenal Syndrome
- Trial name
- NEPH-ROSIS (NCT06000748)
- Testing
- MAP-Target Algorithm
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Francisco
Intrahepatic Cholangiocarcinoma (Icc)
Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (ICC), the second most prevalent primary malignant liver neoplasm, features highly aggressive biological behavior and dismal prognosis.
- Trial name
- LPHAIC for ICC (NCT07646717)
- Testing
- hepatic arterial infusion chemotherapy (Irinotecan liposome plus 5-FU/LV) combined with lenvatinib and PD-1 inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Liver Cirrhosis, Portal Hypertension.
Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension
In the genesis and maintenance of PH associated with liver cirrhosis are two mechanisms that act synergistically. The first is an increase in hepatic vascular resistance, due in part to the disruption of liver structure inherent…
- Trial name
- SIMBETA (NCT01282385)
- Testing
- Simvastatin
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Non-alcoholic Fatty Liver Disease
The Effects of Type of Exercise in Non-alcoholic Fatty Liver Disease
The type of physical activity such as, aerobic or resistant exercise required to reduce liver fat content in patient with non-alcoholic fatty liver disease (NAFLD) remains unclear.
- Trial name
- NCT02679417
- Testing
- exercise
- Where
- Thailand
- Volunteers
- 38 people
- Sponsor
- Mahidol University
Cirrhosis, Myosteatosis
Protocol for Muscle Attenuation Cut-offs in Cirrhosis
The goal of this observational study is to learn if new muscle attenuation cut-offs for the definition of myosteatosis can better predict survival in patients with cirrhosis.
- Conditions
- Cirrhosis, Myosteatosis, Sarcopenia, Sarcopenia in Liver Cirrhosis
- Trial name
- Myocirrhosis (NCT06593015)
- Testing
- Radiological tool for the diagnosis of myosteatosis
- Where
- Italy
- Volunteers
- 1,296 people
- Sponsor
- University of Roma La Sapienza
Liver Cirrhosis, Cognitive Dysfunction
The Liver Cirrhosis Cognitive Decline Scale (LiCCoS)
The goal of this observational study is to develop and test a new questionnaire called the Liver Cirrhosis Cognitive Decline Scale (LiCCoS) for adults with liver cirrhosis.
- Conditions
- Liver Cirrhosis, Cognitive Dysfunction, Hepatic Encephalopathy, Neurocognitive Disorders
- Trial name
- LiCCoS (NCT07418008)
- Where
- India
- Volunteers
- 230 people
- Sponsor
- University of Malaya
Cirrhosis, HCC - Hepatocellular Carcinoma
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
We will give an anticoagulant against portal vein thrombosis, and watch for the results.
- Conditions
- Cirrhosis, HCC - Hepatocellular Carcinoma, Portal Vein Thrombosis
- Trial name
- NCT07132515
- Testing
- Enoxaparin, warfarrin, or apixaban
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Decompensated Cirrhosis, Cirrhotic Cardiomyopathy
Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival
Cirrhosis and portal hypertension are associated with a hyperdynamic circulation and decompensation events, including development of ascites, variceal bleeding, acute kidney injury, and susceptibility to infections.
- Conditions
- Decompensated Cirrhosis, Cirrhotic Cardiomyopathy, Cirrhosis, Liver, Left Ventricular Diastolic Dysfunction
- Trial name
- CIRROSTAT (NCT06431919)
- Testing
- Simvastatin 20mg, Carvedilol 3.125 mg
- Where
- India
- Volunteers
- 260 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Alcoholic Liver Cirrhosis
Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC
This study is to evaluate the safety and efficacy of a single dose of Cellgram™ delivered via hepatic artery in patients with decompensated alcoholic liver cirrhosis.
- Trial name
- NCT03838250
- Testing
- Cellgram™ (Bone marrow-derived MSCs)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Pharmicell Co., Ltd.
Cirrhosis
Spleen Stiffness Measurement With FibroScan
FibroScan® (Echosens, Paris, France) is an active non implantable medical device marketed in Europe since December 2003 and is currently used in many countries.
- Trial name
- NCT02180113
- Testing
- Fibroscan® examination
- Where
- 7 sites in France, Italy and 2 more
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- Echosens
Ascites
Phase Ib of Recombinant Human Albumin Injection
A Randomized, Multicenter,Open-label, positive-controlled, Multi-dose Phase 1 Study to Evaluate the Safety, Tolerance,Efficacy, Pharmacokinetics and Immunogenicity of recombinant human albumin injection in Patients With Hepatic…
- Trial name
- NCT04701697
- Testing
- Recombinant Human Albumin Injection, HumanAlbumin
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The First Hospital of Jilin University
Liver Cirrhosis, Portal Hypertension
Microparticles in Cirrhosis and Portal Hypertension
research on interactions between portal hypertension and microparticles
- Trial name
- MicroCir (NCT02859610)
- Testing
- research on interactions between portal hypertension and microparticles
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon